An FDA spokesman said his agency is “working toward a goal of providing additional guidance” related to marketing CBD for various products and has “made substantial progress.”

An office that serves President Donald Trump is reviewing a draft cannabis guidance document from FDA—possibly signaling progress in the public health agency’s examination of whether and how to regulate the market for CBD in dietary supplements and other products, though some advocacy groups expressed skepticism that the document is related to the latter issues.

The document, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research,” is pending before the White House’s Office of Management and Budget (OMB). OMB received the document May 28, approximately one year after FDA held a widely publicized public meeting about products containing cannabis.

Garrett Graff, managing attorney in Denver with Hoban Law Group, which advises many companies in the hemp industry, said the statement of “substantial progress” by FDA was “somewhat promising insofar as how slow progress has been to date and given the ongoing pandemic.” He said he was anxious to learn further details about the timing of the release of the document pending before OMB, its “substantive content” and other details.

Read the full article on Natural Products Insider